Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncovering regulatory B-cell features associated with regulatory T-cell expansion and global T-cell exhaustion in Waldenström macroglobulinemia <i>Myd88</i> <sup><i>L252P</i></sup> -like lymphoplasmacytic lymphomas.

HemaSphere·2025
Same author

The dual role of TIGIT in regulatory and effector T cells in chronic liver disease.

JHEP reports : innovation in hepatology·2025
Same author

Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells.

Blood advances·2025
Same author

Editorial: Community series in mouse models of B cell malignancies, volume II.

Frontiers in immunology·2024
Same author

The immunoglobulin heavy chain super enhancer controls class switch recombination in developing B cells.

Scientific reports·2024
Same author

Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments.

Journal of leukocyte biology·2024

Related Experiment Video

Updated: Jun 8, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Lipid mediators and human leukemic blasts.

Rémi Fiancette1, Christelle Vincent-Fabert, Estelle Guerin

  • 1Centre National de la Recherche Scientifique, CNRS UMR 6101, Faculté de Médecine, Université de Limoges, 2 rue Dr. Marcland, 87025 Limoges, France.

Journal of Oncology
|October 19, 2010
PubMed
Summary
This summary is machine-generated.

Lipid mediators like prostaglandins and leukotrienes regulate cell growth and apoptosis. This review details their production by leukemic blasts and their impact on leukemia progression.

More Related Videos

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Experiment Videos

Last Updated: Jun 8, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Potent inflammatory mediators, including prostaglandins, leukotrienes, and platelet-activating factor, originate from lipids.
  • These lipid mediators influence crucial cellular processes such as cell proliferation and apoptosis.
  • The specific mechanisms by which these lipid compounds affect leukemic blast growth and apoptosis are not fully understood.

Purpose of the Study:

  • To review current knowledge on lipid mediator production by leukemic blasts.
  • To examine the enzymatic activities involved in lipid mediator synthesis within leukemic cells.
  • To summarize the effects of lipid mediators on leukemic blast growth and apoptosis.

Main Methods:

  • Literature review of studies on lipid mediator production and function in leukemia.
  • Analysis of enzymatic pathways (phospholipase A(2), cyclooxygenases, lipoxygenases) in leukemic blasts.
  • Examination of lipid mediator receptor signaling in leukemic cells.

Main Results:

  • Leukemic blasts produce various lipid mediators, including prostaglandins, leukotrienes, and platelet-activating factor.
  • Key enzymes like phospholipase A(2), cyclooxygenases, and lipoxygenases are involved in their synthesis.
  • These lipid mediators, acting via specific receptors, influence leukemic blast proliferation and apoptosis.

Conclusions:

  • Lipid mediators play a significant role in regulating leukemic blast behavior.
  • Understanding these lipid pathways offers potential therapeutic targets for leukemia treatment.
  • Further research is needed to fully elucidate the complex interactions between lipid mediators and leukemia.